irinotecan + platinum analogues

A combination chemotherapy regimen consisting of **irinotecan**, a topoisomerase I inhibitor, and a **platinum analogue** (commonly cisplatin or carboplatin), an alkylating-like agent that forms DNA crosslinks. This regimen is primarily used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), and is investigated in other solid tumors. Irinotecan inhibits topoisomerase I, leading to DNA damage and apoptosis. Platinum analogues such as cisplatin and carboplatin form DNA crosslinks, inhibiting DNA replication and transcription. Clinical studies and meta-analyses have shown that the irinotecan-plus-platinum combination improves overall survival, progression-free survival, and response rates in ES-SCLC compared to standard etoposide-platinum regimens, with differing toxicity profiles. The regimen is most commonly administered intravenously and requires expert management of toxicity, such as diarrhea and myelosuppression[1][2][4].

Brand names

TopotecinCampto

Other names

irinotecan and platinum analoguesirinotecan plus platinumirinotecan-platinum regimen